https://scholars.lib.ntu.edu.tw/handle/123456789/634143
標題: | Efficacy and Safety of a Parenteral Nutrition Program for Patients with RAS Wild-Type Metastatic Colorectal Cancer Administered First-Line Cetuximab Plus Chemotherapy: A Propensity Score Matching Study | 作者: | Chang, Yu-Tang Chen, Chou-Chen Chang, Shih-Ching Chang, Yu-Yao Lin, Bo-Wen Chen, Hong-Hwa Hsieh, Yao-Yu Hsu, Hung-Chih Hsieh, Meng-Che Kuan, Feng-Che Wu, Chih-Chien Lu, Wei-Chen Su, Yu-Li YI-HSIN LIANG Chen, Joe-Bin Huang, Shuan-Yuan Huang, Ching-Wen Wang, Jaw-Yuan |
關鍵字: | RAS wild-type; cetuximab; metastatic colorectal cancer; supplementary home parenteral nutrition | 公開日期: | 30-六月-2023 | 卷: | 15 | 期: | 13 | 來源出版物: | Nutrients | 摘要: | Malnutrition is a common problem in patients with metastatic colorectal cancer (mCRC) receiving targeted therapy plus chemotherapy, resulting in severe toxicity and decreased survival rates. This retrospective study employing propensity score matching (PSM) examined the efficacy and safety of a supplemental home parenteral nutrition (HPN) program for patients with RAS wild-type mCRC receiving cetuximab plus chemotherapy. This retrospective nationwide registry study included data from 14 medical centers/hospitals across Taiwan, and the data period ranged from November 2016 to December 2020. Patients with RAS wild-type mCRC receiving cetuximab plus chemotherapy as their first-line therapy were included and divided into HPN and non-HPN program groups. HPN was initiated based on patient-specific factors, such as baseline nutritional status, treatment-related toxicities, and comorbidities. Clinical outcomes were evaluated using response to therapy, duration of response (DoR), progression-free survival (PFS), and overall survival (OS). This study recruited 758 patients, of whom 110 and 648 were included in the HPN and non-HPN program groups, respectively. After 1:3 PSM, the data of 109 and 327 patients from the HPN and non-HPN program groups were analyzed, respectively. The HPN program group had a higher metastasectomy rate (33.9% vs. 20.2%, p = 0.005), and longer duration of treatment and DoR than the non-HPN program group (13.6 vs. 10.3 and 13.6 vs. 9.9 months, p = 0.001 and < 0.001, respectively). The HPN program group tended to have a longer median PFS (18.2 vs. 13.9 months, p = 0.102). Moreover, we noted a significant improvement in the median OS in the same group (53.4 vs. 34.6 months, p = 0.002). Supplemental HPN programs may be recommended for select patients with mCRC receiving targeted therapy plus chemotherapy to improve oncological outcomes. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/634143 | ISSN: | 2072-6643 | DOI: | 10.3390/nu15132971 |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。